The development of respiratory syncytial virus (RSV) bronchiolitis in infants within the first 6 months of life was associated with increased odds of pneumonia, otitis media, and filling of antibiotic prescriptions in the second 6 months of life, according to study results published in Clinical Infectious Diseases. This was a population-based cohort study of infants…
Early-onset pneumonia with multidrug-resistant organisms is a major concern for patients who have received a liver transplant, and pre- and intra-operative risk factors influence its development, according to study data presented at The American Association for the Study of Liver Diseases’ The Liver Meeting, held November 8 to 12, 2019 in Boston, Massachusetts. In an…
Patients with Parkinson disease (PD) who use inappropriate antipsychotics may be at an increased risk for pneumonia compared with patients with PD who use more appropriate atypical antipsychotics.
The FDA has approved the supplemental NDA for Baxdela for the treatment of community acquired bacterial pneumonia in adult patients.
Thirty-day readmission following hospitalization for pneumonia is common in patients with underlying comorbidities such as COPD, kidney and heart diseases, and dementia.
A typical usual interstitial pneumonia pattern was the predominant radiologic pattern seen in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.
Delafloxacin may provide a feasible alternative antibiotic monotherapy option for treating patients with community-acquired bacterial pneumonia (CABP) who have renal impairment in both inpatient and outpatient settings.
Children with neurologic impairment had lower rates of recurrent severe pneumonia if they practiced dental care as a preventive measure.
The ATS and IDSA have presented recommendations for the diagnosis and management of community-acquired pneumonia.
Lefamulin appears to be noninferior in safety and efficacy compared with moxifloxicin in the treatment of community-acquired bacterial pneumonia.
A new scoring system for Drug Resistance in Pneumonia (DRIP) has demonstrated efficacy in improving pneumonia-related prescription trends, including a significant drop in broad-spectrum antibiotic prescriptions.
A prevention bundle composed of 7 interventions for patients at high-risk for non-ventilator hospital-acquired pneumonia (HAP) was effective in significantly reducing HAP rates.
Researchers conducted a Phase 3 trial of patients with community acquired bacterial pneumonia and diabetes to compare delafloxacin treatment with moxiflocacin.
Study results showed that heavy tracheal colonization aided the identification of patients at higher risk of developing bacterial respiratory infections.
The recent cluster of pulmonary illnesses related to electronic cigarette use appears to represent an emerging clinical syndrome or syndromes.
Serotype-specific IgG responses to the pneumococcal vaccine Pneumovax®23 were greater in patients with subnormal IgG1 than subnormal IgG3.
Pneumococcal colonization rates are low in recipients of solid organ transplants, but most of the colonizing serotypes are not included in pneumococcal vaccines.
The FDA has approved Xenleta (lefamulin; Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Mycoplasma pneumoniae immunoglobulin M antibody-secreting cells were successfully used to differentiate between those with M pneumoniae infection and carriers in a pediatric population.
The use of corticosteroids in people with influenza pneumonia may increase rates of mortality.